Linda L. Restifo

Linda L. Restifo

Auto-generated profile, based on publicly available information

Linda L. Restifo

Department of Cellular & Molecular Medicine University of Arizona Tucson AZ USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Disease Models & Mechanisms
Verified
Journal Article
Open access
LRLinda L. Restifo
Linda L. Restifo
GPGerald R. Phelan
Gerald R. Phelan
Summary: Despite remarkable advances in basic biomedical science that have led to improved patient care, there is a wide and persistent gap in the abilities of researchers and clinicians to understand and appreciate each other. In this Editorial, the authors, a scientist and a clinician, discuss the rift between practitioners of laboratory research and clinical medicine. Using their first-hand experience and numerous interviews throughout the United States, they explore the causes of this ‘cultural divide’. Members of both professions use advanced problem-solving skills and typically embark on their career paths with a deeply felt sense of purpose. Nonetheless, differences in classroom education, professional training environments, reward mechanisms and sources of drive contribute to obstacles that inhibit communication, mutual respect and productive collaboration. More than a sociological curiosity, the cultural divide is a significant barrier to the bench-to-bedside goals of translational medicine. Understanding its roots is the first step towards bridging the gap.

16 May 2005 in Journal of Comparative Neurology
Verified
Journal Article
Open access
PDF file
CCChristos Consoulas
Christos Consoulas
RLRichard B. Levine
Richard B. Levine
LRLinda L. Restifo
Linda L. Restifo
Dendrites are subject to subtle modifications as well as extensive remodeling during the assembly and maturation of neural circuits in a wide variety of organisms. During metamorphosis, Drosophila flight motoneurons MN1–MN4 undergo dendritic regression, followed by regrowth, whereas MN5 differentiates de novo (Consoulas et al. [2002] J. Neurosci. 22:4906–4917). Many cellular changes during metamorphosis are triggered and orchestrated by the steroid hormone 20‐hydroxyecdysone, which initiates a cascade of coordinated gene expression. Broad Complex (BRC), a primary response gene in the ecdysone cascade, encodes a family of transcription factors (BRC‐Z1–Z4) that are essential for metamorphic reorganization of the central nervous system (CNS). Using neuron‐filling techniques that reveal cellular morphology with very high resolution, we tested the hypothesis that BRC is required for metamorphic development of MN1–MN5. Through a combination of loss‐of‐function mutant analyses, genetic mapping, and transgenic rescue experiments, we found that 2Bc function, mediated by BRC‐Z3, is required selectively for motoneuron dendritic regrowth (MN1–MN4) and de novo outgrowth (MN5), as well as for soma expansion of MN5. In contrast, larval development and dendritic regression of MN1–MN4 are BRC‐independent. Surprisingly, BRC proteins are not expressed in the motoneurons, suggesting that BRC‐Z3 exerts its effect in a non‐cell‐autonomous manner. The 2Bc mutants display no gross defects in overall thoracic CNS structure, or in peripheral structures such as target muscles or sensory neurons. Candidates for mediating the effect of BRC‐Z3 on dendritic growth of MN1–MN5 include their synaptic inputs and non‐neuronal CNS cells that interact with them through direct contact or diffusible factors. J. Comp. Neurol. 485:321–337, 2005.

9 November 2020 in Journal of Neurogenetics
Verified
Journal Article
Open access
DADavid R. Andrew
David R. Andrew
MMMariah E. Moe
Mariah E. Moe
DCDailu Chen
Dailu Chen
JTJudith A. Tello
Judith A. Tello
RDRachel L. Doser
Rachel L. Doser
LRLinda L. Restifo
Linda L. Restifo
Mutations in hundreds of genes cause neurodevelopmental disorders with abnormal motor behavior alongside cognitive deficits. Boys with fragile X syndrome (FXS), a leading monogenic cause of intellectual disability, often display repetitive behaviors, a core feature of autism. By direct observation and manual analysis, we characterized spontaneous-motor-behavior phenotypes of Drosophila dfmr1 mutants, an established model for FXS. We recorded individual 1-day-old adult flies, with mature nervous systems and prior to the onset of aging, in small arenas. We scored behavior using open-source video-annotation software to generate continuous activity timelines, which were represented graphically and quantitatively. Young dfmr1 mutants spent excessive time grooming, with increased bout number and duration; both were rescued by transgenic wild-type dfmr1+ . By two grooming-pattern measures, dfmr1-mutant flies showed elevated repetitions consistent with perseveration, which is common in FXS. In addition, the mutant flies display a preference for grooming posterior body structures, and an increased rate of grooming transitions from one site to another. We raise the possibility that courtship and circadian rhythm defects, previously reported for dfmr1 mutants, are complicated by excessive grooming. We also observed significantly increased grooming in CASK mutants, despite their dramatically decreased walking phenotype. The mutant flies, a model for human CASK-related neurodevelopmental disorders, displayed consistently elevated grooming indices throughout the assay, but transient locomotory activation immediately after placement in the arena. Based on published data identifying FMRP-target transcripts and functional analyses of mutations causing human genetic neurodevelopmental disorders, we propose the following proteins as candidate mediators of excessive repetitive behaviors in FXS: CaMKIIα, NMDA receptor subunits 2A and 2B, NLGN3, and SHANK3. Together, these fly-mutant phenotypes and mechanistic insights provide starting points for drug discovery to identify compounds that reduce dysfunctional repetitive behaviors.

28 October 2021 in Genetics
Verified
Journal Article
Open access
PDF file
LRLinda L Restifo
Linda L Restifo
In the late 20th century, identification of the major protein components of amyloid plaques and neurofibrillary tangles provided a window into the molecular pathology of Alzheimer’s disease, ushering in an era of optimism that targeted therapeutics would soon follow. The amyloid-cascade hypothesis took hold very early, supported by discoveries that dominant mutations in APP, PSEN1, and PSEN2 cause the very rare, early-onset, familial forms of the disease. However, in the past decade, a stunning series of failed Phase-3 clinical trials, testing anti-amyloid antibodies or processing-enzyme inhibitors, prompts the question, What went wrong? The FDA’s recent controversial approval of aducanumab, despite widespread concerns about efficacy and safety, only amplifies the question. The assumption that common, late-onset Alzheimer’s is a milder form of familial disease was not adequately questioned. The differential timing of discoveries, including blood–brain–barrier-penetrant tracers for imaging of plaques and tangles, made it easy to focus on amyloid. Furthermore, the neuropathology community initially implemented Alzheimer’s diagnostic criteria based on plaques only. The discovery that MAPT mutations cause frontotemporal dementia with tauopathy made it even easier to overlook the tangles in Alzheimer’s. Many important findings were simply ignored. The accepted mouse models did not predict the human clinical trials data. Given this lack of pharmacological validity, input from geneticists in collaboration with neuroscientists is needed to establish criteria for valid models of Alzheimer’s disease. More generally, scientists using genetic model organisms as whole-animal bioassays can contribute to building the pathogenesis network map of Alzheimer’s disease.

1 January 2023 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
LRLinda L Restifo
Linda L Restifo
RERobert P Erickson
Robert P Erickson
A 77-year-old woman had 2 weeks of fever and flu-like symptoms starting several hours after receiving an mRNA booster for SARS-CoV-2 and the influenza vaccine, in separate shots. Laboratory tests showed cholangitis. Medical history included APOE-ε4 carrier genotype, mild Alzheimer’s disease, participation in a clinical trial of aducanumab, and resolving polymyalgia rheumatica. The patient recovered with at-home supportive care. She had aducanumab-associated amyloid-related imaging abnormalities–edema (ARIA-E) both before and after the acute cholangitis. Two months following the vaccinations polymyalgia rheumatica recurred. This case raises questions about interactions among immune-mediated disease, complications of anti-amyloid monoclonal antibodies, and adverse events following SARS-CoV-2 mRNA vaccination.

30 May 2026 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
AHAdrianne G. Huxtable
Adrianne G. Huxtable
EFEmily G. Flanigan
Emily G. Flanigan
MFMichael L. Frazure
Michael L. Frazure
LWLila B. Wollman
Lila B. Wollman
CSChenbo Sun
Chenbo Sun
RFRalph F. Fregosi
Ralph F. Fregosi